Skip to main content
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. — Investor Relations & Filings

Ticker · SRPT ISIN · US8036071004 LEI · 549300IKDPIED8J8IG21 US Manufacturing
Open in API
Filings indexed 1,061 across all filing types
Latest filing 2025-12-11 Capital/Financing Update
Country US United States of America
Listing US SRPT

About Sarepta Therapeutics, Inc.

https://www.sarepta.com/

Sarepta Therapeutics is a commercial-stage biopharmaceutical company that engineers precision genetic medicines for rare diseases. The company's research and development efforts are centered on RNA-targeted therapeutics and gene therapies, with a primary focus on treating rare neuromuscular and central nervous system disorders. Sarepta aims to accelerate the drug development process from discovery to patient application and is building significant gene therapy manufacturing capabilities to support its mission.

Recent filings

Filing Released Lang Actions
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 10, 2025. It details a specific transaction involving the exchange of convertible senior notes, including terms of the exchange, parties involved, and related legal and regulatory information. The document does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. Instead, it focuses on a capital transaction and related disclosures. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (8070 characters) and content confirm it is a substantive filing about a financing event, not merely an announcement or a certification. Therefore, the appropriate classification is CAP with high confidence.
2025-12-11 English
4
Director's Dealing
2025-12-10 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 7, 2025, reporting the grant of equity awards to the CEO, Douglas S. Ingram. The key content is about a management compensation event and changes related to senior management equity awards. The document includes details about the equity awards and references the employment agreement and equity incentive plan. The filing is specifically under Item 5.02, which relates to departure or appointment of directors or officers and compensatory arrangements. This matches the category for Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management, including compensation grants. The document is not a full financial report, earnings release, or proxy statement, but a current report on management compensation. Therefore, the correct classification is MANG with high confidence.
2025-12-08 English
4
Director's Dealing
2025-12-03 English
4
Director's Dealing
2025-11-20 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.